Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Cancer Res. 2018 Mar 20;78(11):3075–3086. doi: 10.1158/0008-5472.CAN-17-3024

Figure 7. Venetoclax/GDC-0980 is effective in AML cells exhibiting various forms of venetoclax resistance.

Figure 7

(A–B) venetoclax-sensitive (MV4-11S, MOLM-13S) or venetoclax-resistant (MV4-11R, MOLM-13R) cells were exposed to the designated concentrations of venetoclax alone or in combination with 500 nM GDC-0980 for 24 hr after which cell growth and viability was assessed using the CellTiter-Glo luminescent assay. Error Bars, S.D for at least 3 independent experiments. P < 0.01 for combined treatment compared to venetoclax alone for each concentration in each cell line. (C) MV4-11 cells were cultured in the presence or absence of GFP-labeled HS-5 stromal cells for 48 hr then exposed to venetoclax ± GDC-0980 (10 and 500 nM respectively) for 5 hr after which, cells were stained with 7-AAD for 30 min and photographed as described in Methods. Alternatively, the extent of apoptosis was determined in MV4-11 cells (GFP-negative population) using the Annexin V-APC staining (Fig. 7D). Error Bars, S.D for 4 independent experiments.